

References

CHAPTER 1

- ¹ Cauvin HE. Zimbabwe's sad lack: Land to bury AIDS victims. *The New York Times*. March 1, 2000: A4.
- ² UNAIDS. Epidemiological Fact Sheet on HIV/AIDS and Sexually Transmitted Infections, 2000 Update—Zimbabwe. 2000.
- ³ UNAIDS. Epidemiological Fact Sheet on HIV/AIDS and Sexually Transmitted Infections, 2000 Update—Zimbabwe. 2000; World Health Organization. *Anti-tuberculosis drug resistance in the world: the WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance 1994–1997*. Geneva: World Health Organization, 1997.
- ⁴ World Health Organization. *World Health Report. Health Systems: Improving Performance*. Geneva: World Health Organization, 2000; World Health Organization. Online Statistical Index. Accessed on: February 7, 2001. Internet communication at: <http://www.nt.who.int/whosis/statistics/menu.cfm?path=statistics,basic&language=english>.
- ⁵ Kenyon TA, Valway SE, Ihle WW, et al. Transmission of multidrug-resistant *Mycobacterium tuberculosis* during a long airplane flight. *N Engl J Med*. 1996;334:933–8.
- ⁶ Kenyon TA, Valway SE, Ihle WW, Onorato IM, Castro KG. Transmission of multidrug-resistant *Mycobacterium tuberculosis* during a long airplane flight. *N Engl J Med*. 1996;334:933–8.
- ⁷ World Health Organization. *Anti-tuberculosis drug resistance in the world: the WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance 1994–1997*. Geneva: World Health Organization, 1997; Zimmermann, T. Fighting TB: a second chance to do it right. *US News and World Report*. March 31, 1997.
- ⁸ Pablos-Méndez A, Raviglione MC, Laszlo A, et al. Global surveillance for antituberculosis-drug resistance, 1994–1997. World Health Organization–International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. *N Engl J Med*. 1998;338:1641–9.
- ⁹ Cave AJE. The evidence for the incidence of tuberculosis in ancient Egypt. *British Journal of Tuberculosis*. 1939;33:142.
- ¹⁰ Dye C, Scheele S, Dolin P, Pathania V, and Raviglione MC. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. *JAMA*. 1999; 282(7):677–86; World Health Organization. *Global Tuberculosis Control: WHO Report 1999*. Geneva: World Health Organization, 1999.
- ¹¹ Bloom BR, Murray CJ. Tuberculosis: commentary on a reemergent killer. *Science*. 1992;257:1055–64; Dolin PJ, Raviglione MC, Kochi A. Global tuberculosis incidence and mortality during 1990–2000. *Bull World Health Organ*. 1994;72:213–20; Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. *JAMA*. 1999;282:677–86; Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. *Lancet*. 1997;349:1498–504; Raviglione MC, Snider DE Jr, Kochi A. Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. *JAMA*. 1995;273:220–6; World Health Organization. *Tuberculosis control: the DOTS strategy: an annotated bibliography compiled by the Global Tuberculosis Programme and the Regional Office for South-East Asia*. Geneva: World Health Organization, 1997.
- ¹² World Health Organization. *Global Tuberculosis Control: WHO Report 2001*. Geneva: World Health Organization, 2001.
- ¹³ World Health Organization. *Global Tuberculosis Control: WHO Report 2001*. Geneva: World Health Organization, 2001.
- ¹⁴ Raviglione MC, Dye C, Schmidt S, Kochi A. Assessment of worldwide tuberculosis control. WHO Global Surveillance and Monitoring Project. *Lancet*. 1997;350:624–9; World Health Organization. *Tuberculosis and Sustainable Development: Report from the Ministerial Conference in Amsterdam*. Geneva: World Health Organization, 2000. WHO/CDS/STB/2000.6.
- ¹⁵ Dye C, Garnett GP, Sleeman K, Williams BG. Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy. *Lancet*. 1998;352:1886–91; Murray CJL, Styblo K, and Rouillon A. Tuberculosis. In: Jamison DT, World Bank; *Disease Control Priorities in Developing Countries*. New York, N.Y.: Oxford University Press (published for the World Bank), 1993.
- ¹⁶ Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. *Lancet*. 1997;349:1498–504.
- ¹⁷ de Jonghe E, Murray CJ, Chum HJ, et al. Cost-effectiveness of chemotherapy for sputum smear-positive pulmonary tuberculosis in Malawi, Mozambique and Tanzania. *Int J Health Plann Manage*. 1994;9:151–81; Jha P, Bangoura O, Ranson K. The cost-effectiveness of forty health interventions in Guinea. *Health Policy Plan*. 1998;13:249–62; World Bank. *World Development Report: Investing in Health*. Washington: World Bank, 1993.
- ¹⁸ Kochi A. Tuberculosis control—is DOTS the health breakthrough of the 1990s? *World Health Forum*. 1997;18:225–32; discussion 233–47.
- ¹⁹ World Health Organization. *Global Tuberculosis Control: Surveillance, Planning and Financing*. WHO Report 2002. Geneva, Switzerland, WHO/CDS/TB/2002.295.
- ²⁰ Raviglione MC, Dye C, Schmidt S, Kochi A. Assessment of worldwide tuberculosis control.
- ²¹ Murray CJ, Salomon JA. Modeling the impact of global tuberculosis control strategies. *Proc Natl Acad Sci U S A*. 1998;95:13881–6.
- ²² Raviglione MC, Snider DE, and Kochi A. Global epidemiology of tuberculosis: morbidity and mortality of a worldwide epidemic. *JAMA*. 1995; 273(3):220–226.
- ²³ González E, Armas L, Alonso A. Tuberculosis in the Republic of Cuba: its possible elimination. *Tuber Lung Dis*. 1994;75:188–94; Henderson DA. The challenge of eradication: lessons from past eradication campaigns. *Int J Tuberc Lung Dis*. 1998;2:S4–8; Kok-Jensen A. [When can tuberculosis be eradicated in Denmark?]. *Ugeskr Laeger*. 1995; 157(3):273–9; Ohmori M. [Estimating the year of eradication of tuberculosis in Japan]. *Kekkaku*. 1991; 66(12):819–28.

- ²⁴Bloom BR, Murray CJ. Tuberculosis: commentary on a reemergent killer. *Science*. 1992;257:1055–64; Fatkenheuer G, Taelman H, Lepage P, et al. The return of tuberculosis. *Diagn Microbiol Infect Dis*. 1999;34:139–46; Nolan CM. Multidrug-resistant tuberculosis in the USA: the end of the beginning. *Tuber Lung Dis*. 1996;77:293–4; Nolan CM. Nosocomial multidrug-resistant tuberculosis—global spread of the third epidemic. *J Infect Dis*. 1997;176:748–51; Raviglione MC, Rieder HL, Styblo K, et al. Tuberculosis trends in eastern Europe and the former USSR. *Tuber Lung Dis*. 1994;75:400–16.
- ²⁵Griffith DE. The United States and worldwide tuberculosis control: a second chance for Prince Prospero. *Chest*. 1998;113:1434–6.
- ²⁶World Health Organization. *Economic Impacts of Tuberculosis*. Geneva: World Health Organization, 2000.
- ²⁷Kamolratanakul P, Sawert H, Kongsin S, et al. Economic impact of tuberculosis at the household level. *Int J Tuberc Lung Dis*. 1999;3:596–602.
- ²⁸Saunders PR. An economic evaluation of alternative programme designs for tuberculosis control in rural Uganda. *Soc Sci Med*. 1995;40:1203–12.
- ²⁹World Health Organization. *Tuberculosis and Sustainable Development: Report from the Ministerial Conference in Amsterdam*. Geneva: World Health Organization, 2000. WHO/CDS/STB/2000.6.
- ³⁰Devi S, Ganapathy S, Sivasubramanian, MR, et al. *Behaviour pattern of chest symptomatics in urban and rural population*. Report submitted to WHO Regional Office for South-East Asia, n.d; Pathania V, Almeida J, and Kochi A. *TB patients and private for-profit health care providers in India*. TB Research No. 1. Geneva: The Global TB Programme, World Health Organization, 1997. WHO/TB/97.223.
- ³¹Murray CJL and Lopez AD. *Global health statistics: a compendium of incidence, prevalence and mortality estimates for over 200 conditions*. Cambridge: Harvard University Press, 1996; World Bank. *World Development Report: Investing in Health*. Washington: World Bank, 1993.
- ³²Holmes CB, Hausler H, Nunn P. A review of sex differences in the epidemiology of tuberculosis. *Int J Tuberc Lung Dis*. 1998;2:96–104; Hudelson P. Gender differentials in tuberculosis: the role of socio-economic and cultural factors. *Tuber Lung Dis*. 1996;77:391–400; Murray CJ. Social, economic and operational research on tuberculosis: recent studies and some priority questions. *Bull Int Union Tuberc Lung Dis*. 1991;66:149–56.
- ³³Rajeswari R, Balasubramanian R, Muniyandi M et al. Socio-economic impact of tuberculosis on patients and family in India. *Int J Tuberc Lung Dis*. 1999;3:869–77.
- ³⁴Pablos-Méndez A, Raviglione MC, Laszlo A, et al. Global surveillance for antituberculosis-drug resistance, 1994–1997. World Health Organization—International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. *N Engl J Med*. 1998;338:1641–9; World Health Organization. *Anti-tuberculosis drug resistance in the world: the WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance 1994–1997*. Geneva: World Health Organization, 1997.
- ³⁵Dye C, Espinal M, Watt C, et al. *Worldwide incidence of multidrug-resistant tuberculosis*, unpublished; Espinal MA, Laszlo A, Simonsen L, et al. Global trends in resistance to antituberculosis drugs. World Health Organization—International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. *N Engl J Med*. 2001;344:1294–303; Mercedes Becerra (personal communication); World Health Organization, International Union Against Tuberculosis and Lung Diseases. *Anti-tuberculosis Drug Resistance in the World, Report n°2 Prevalence and trends. WHO–IUATLD Global project on anti-tuberculosis drug resistance surveillance*. Geneva: World Health Organization, 2000. WHO/CDS/TB/2000; Program in Infectious Disease and Social Change. *The global impact of drug-resistant tuberculosis*. Boston: Harvard University and Open Society Institute, 1999.
- ³⁶World Health Organization. *Anti-tuberculosis drug resistance in the world: the WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance 1994–1997*. Geneva: World Health Organization, 1997.
- ³⁷Espinal MA, Kim SJ, Suárez PG, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. *JAMA*. 2000;283:2537–45.
- ³⁸Espinal MA, Kim SJ, Suárez PG, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. *JAMA*. 2000;283:2537–45; Iseman MD. MDR-TB and the developing world—a problem no longer to be ignored: the WHO announces 'DOTS Plus' strategy. *Int J Tuberc Lung Dis*. 1998;2:867; World Health Organization. *Coordination of DOTS-Plus pilot projects for the management of MDR-TB*. Geneva: World Health Organization, 1999.
- ³⁹Iseman MD, Cohn DL, Sbarbaro JA. Directly observed treatment of tuberculosis. We can't afford not to try it. *N Engl J Med*. 1993;328:576–8; Farmer PE; Bayona J; Becerra M; Kim JY, and Shin S. Reducing transmission through community-based treatment of multidrug-resistant tuberculosis. *Int J Tuberc Lung Dis*. 1998; 2(11 Suppl. 1):S190.
- ⁴⁰Iseman MD. Tailoring a time-bomb. Inadvertent genetic engineering. *Am Rev Respir Dis*. 1985;132:735–6.
- ⁴¹Program in Infectious Disease and Social Change. *The global impact of drug-resistant tuberculosis*. Boston: Harvard University and Open Society Institute, 1999.
- ⁴²Program in Infectious Disease and Social Change. *The global impact of drug-resistant tuberculosis*. Boston: Harvard University and Open Society Institute, 1999.
- ⁴³Steenland K, Levine AJ, Sieber K, Schulte P, Aziz D. Incidence of tuberculosis infection among New York State prison employees. *Am J Public Health*. 1997;87:2012–4; Ikeda RM, Birkhead GS, DiFerdinando GT Jr, et al. Nosocomial tuberculosis: an outbreak of a strain resistant to seven drugs. *Infect Control Hosp Epidemiol*. 1995;16:152–9; Kimerling ME, Kluge H, Vezhnina N, et al. Inadequacy of the current WHO re-treatment regimen in a central Siberian prison: treatment failure and MDR-TB. *Int J Tuberc Lung Dis*. 1999;3:451–3; Valway SE, Richards SB, Kovacovich J, Greifinger RB, Crawford JT, Dooley SW. Outbreak of multi-drug-resistant tuberculosis in a New York State prison, 1991. *Am J Epidemiol*. 1994;140:113–22.
- ⁴⁴Amnesty International. *Annual Report 1999: Russian Federation*. London: Amnesty International, 1999. Internet communication at: <http://www.amnesty.org/ailib/aireport/ar99/eur46.htm>.
- ⁴⁵Walmsley, Roy. *World Prison Population List*. Home Office Research, Development and Statistics Directorate: 1999. Internet communication at: <http://www.homeoffice.gov.uk/rds/pdfs/r88.pdf>.
- ⁴⁶Program in Infectious Disease and Social Change. *The global impact of drug-resistant tuberculosis*. Boston: Harvard University and Open Society Institute, 1999.

- ⁴⁷ Curtis AB, Ridzon R, Novick LF, et al. Analysis of *Mycobacterium tuberculosis* transmission patterns in a homeless shelter outbreak. *Int J Tuberc Lung Dis.* 2000;4:308–13.
- ⁴⁸ Barclay DM 3rd, Richardson JP, Fredman L. Tuberculosis in the homeless. *Arch Fam Med.* 1995;4:541–6.
- ⁴⁹ Pavlovic M, Simic D, Krstic-Buric M, et al. Wartime migration and the incidence of tuberculosis in the Zagreb region, Croatia. *Eur Respir J.* 1998;12:1380–3; Houston S. Tuberculosis in refugees and displaced persons. *Int J Tuberc Lung Dis.* 1998;2:S94–7; Gibson N, Boillot F, Jalloh H. The cost of tuberculosis to patients in Sierra Leone's war zone *Int J Tuberc Lung Dis.* 1998;2:726–31.
- ⁵⁰ Kenyon TA, Valway SE, Ihle WW; et al. Transmission of multidrug-resistant *Mycobacterium tuberculosis* during a long airplane flight. *N Engl J Med.* 1996; 334(15):933–938.
- ⁵¹ Agerton TB, Valway SE, Blinkhorn RJ, et al. Spread of strain W, a highly drug-resistant strain of *Mycobacterium tuberculosis*, across the United States. *Clin Infect Dis.* 1999;29:85–92; discussion 93–5; Bifani PJ, Plikaytis BB, Kapur V, et al. Origin and interstate spread of a New York City multidrug-resistant *Mycobacterium tuberculosis* clone family. *JAMA.* 1996;275:452–7; Casper C, Singh SP, Rave S, et al. The transcontinental transmission of tuberculosis: A molecular epidemiological assessment. *Am J Public Health.* 1996;86:551–3; Codina G, Vidal R, Martin-Casabona N, et al. Multidrug-resistant tuberculosis caused by 'W'-related strains in three immunocompetent foreign-born patients. *Int J Tuberc Lung Dis.* 1999;3:82–4; Kreiswirth, 1999. (Personal communication).
- ⁵² Farmer, P. Social inequalities and emerging infectious diseases. *Emerg Infect Dis.* 1996 Oct-1996 Dec 31; 2(4):259–69. International Chamber of Commerce. (1997). World business calls globalization a powerful force for economic progress. Press Release. 18 June 1997.
- ⁵³ International Chamber of Commerce. (1997). World business calls globalization a powerful force for economic progress. Press Release. 18 June 1997

CHAPTER 2

- ¹ Dye C, Scheeles S, Dolin P, Pathania V, Raviglione MC. Global burden of tuberculosis: Estimated incidence, prevalence, and mortality by country. *JAMA,* 1999; 282, 677–686
- ² Dye, C., Fengzeng, Z., Scheele, S., and Williams, B. (2000) Evaluating the impact of tuberculosis control: number of deaths prevented by short-course chemotherapy in China. *International Journal of Epidemiology,* 29(3), 558–64.
- ³ World Health Organization. *Global Tuberculosis Control. WHO Report 2001.* Geneva: World Health Organization, 2001. WHO/CDS/TB/2001.287.
- ⁴ Results of directly observed short-course chemotherapy in 112,842 Chinese patients with smear-positive tuberculosis. China Tuberculosis Control Collaboration. *Lancet.* 1996;347:358–62.
- ⁵ Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. *N Engl J Med.* 1994;330:1179–84.
- ⁶ Farmer P, Leandre F, Mukherjee JS, et al. Community-based approaches to HIV treatment in resource-poor settings. *Lancet.* 2001;358:404–9.
- ⁷ World Health Organization. 105th Session of the Executive Board of the World Health Organisation. *Stop TB Initiative. Report by the Director General.* Geneva: World Health Organization, 1999. Internet communication at: <http://www.stoptb.org/material/dgebreportstoptb>.
- ⁸ Results of directly observed short-course chemotherapy in 112,842 Chinese patients with smear-positive tuberculosis. China Tuberculosis Control Collaboration. *Lancet.* 1996;347:358–62.
- ⁹ Khatri GR, Frieden TR. The status and prospects of tuberculosis control in India. *Int J Tuberc Lung Dis.* 2000;4:193–200.
- ¹⁰ World Health Organization. Global Tuberculosis Control. *WHO Report 2000.* Geneva: World Health Organization, 2000. Internet communication at: <http://www.who.int/grb/publications/globrep00/index.html>.
- ¹¹ Appaix, Olivier. *Tuberculosis Control: Financial Evaluation for the 2001–2005 Period (in Low- and Lower Middle-Income Countries). Economic Annex to the Global Plan to Stop TB* Boston: Partners In Health, to be published in 2002; World Health Organization. *Global Tuberculosis Control. WHO Report 2000.* Geneva: World Health Organization, 2000. WHO/CDS/TB/2000.275.
- ¹² World Health Organization. *Global tuberculosis programme. Report of the ad hoc committee on the tuberculosis epidemic.* Geneva: World Health Organization, 1998.
- ¹³ Hurlig AK, Porter JD, Ogden JA. Tuberculosis control and directly observed therapy from the public health/human rights perspective. *Int J Tuberc Lung Dis.* 1999;3:553–60.
- ¹⁴ World Health Organization. *World Health Report 2000. Health systems: Improving performance.* Geneva: World Health Organization, 2000.
- ¹⁵ Appaix, Olivier. *Tuberculosis Control: Financial Evaluation for the 2001–2005 Period (in Low- and Lower Middle-Income Countries). Economic Annex to the Global Plan to Stop TB* Boston: Partners In Health, to be published in 2002.
- ¹⁶ World Health Organization. *Conference report: Tuberculosis and sustainable development, 22–24 March 2000.* Geneva: World Health Organization, 2000. Internet communication at: <http://www.stoptb.org/conference/index.html>.
- ¹⁷ Dye C, Garnett GP, Sleeman K, Williams BG. Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy. *Lancet.* 1998;352:1886–91.
- ¹⁸ G8 Countries. Chair's Summary Okinawa International Conference on Infectious Diseases. Internet communication at: http://www.g8.gc.ca/2000/okinawa_infectious_diseases-e.asp; Watts J. G8 nations to set up infectious-disease fund (News). *Lancet.* 2000;355:2060; World Health Organization. *World Health Report. Health Systems: Improving Performance.* Geneva: World Health Organization, 2000.
- ¹⁹ Bosman MC. Health sector reform and tuberculosis control: the case of Zambia. *Int J Tuberc Lung Dis.* 2000;4:606–14.
- ²⁰ World Health Organization. *Global TB Drug Facility Prospectus.* Geneva: World Health Organization, 2001. WHO/CDS/STB/2001.10a.
- ²¹ World Health Organization. *Involving Private Practitioners in Tuberculosis Control.* Geneva: World Health Organization, 2001.

WHO/CDS/TB/2001.285.

- 22 Peruvian Ministry of Health. *Tuberculosis en el Perú, Informe 1999*. Lima: Programa Nacional de Control de la Tuberculosis, 2000.
- 23 World Health Organization. *Global DOTS Expansion Plan: Progress in TB control in high-burden countries, 2001*. Geneva: World Health Organization, 2001. WHO/CDS/STB/2001.11.
- 24 Espinal MA, Kim SJ, Suárez PG, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. *JAMA*. 2000;283:2537–45.

CHAPTER 3

- 1 Mann JM, Tarantola D, Global AIDS Policy Coalition; *AIDS in the World II Global Dimensions, Social Roots, and Responses*. New York: Oxford University Press, 1996.
- 2 UNAIDS. *AIDS epidemic update: December 2000*. Geneva: UNAIDS, 2000.
- 3 International Federation of Red Cross and Red Crescent Societies. *World Disaster Report 2000*. Geneva: International Federation of Red Cross and Red Crescent Societies, 2000; Garrett L. Of epidemic proportions/UN report: AIDS deaths to surpass plague, Spanish flu. *Newsday*. November 29, 2000: A08.
- 4 Garrett L. (2000) Of epidemic proportions/UN report: AIDS deaths to surpass plague, Spanish flu. *Newsday*, 29 November A08.
- 5 Farmer PE, Walton DA, Furin JJ. The changing face of AIDS: implications for policy and practice. In: Mayer KH, Pizer H, American Public Health Association; *The Emergence of AIDS: The Impact on Immunology, Microbiology, and Public Health*. Washington: American Public Health Association, 2000.
- 6 Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. *Lancet*. 1998;352:1725–30; Moore RD, Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. *AIDS*. 1999;13:1933–42; Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. *N Engl J Med*. 1998;338:853–60.
- 7 Moore RD, Chaisson RE. (1999). Natural history of HIV infection in the era of combination antiretroviral therapy. *AIDS*, 13(14), 1933–42.
- 8 Palella FJ, Delaney KM, Moorman AC et al. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. *New England Journal of Medicine*, 338, 853–60.
- 9 UNAIDS Epidemic Update, December 2001. World Health Organization. Geneva. 2001 internet communication at: http://www.unaids.org/worldaidsday/2001/Epiupdate2001/Epiupdate2001_en.pdf
- 10 Raviglione MC, Snider DE Jr, Kochi A. Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. *JAMA*. 1995;273:220–6.
- 11 Cantwell MF, Binkin NJ. Impact of HIV on tuberculosis in sub-Saharan Africa: a regional perspective. *Int J Tuberc Lung Dis*. 1997;1:205–14.
- 12 De Cock KM, Soro B, Coulibaly IM, Lucas SB. Tuberculosis and HIV infection in sub-Saharan Africa. *JAMA*. 1992; 268: 1581-7.
- 13 Dye C, Corbett L, Watt C, Walker, N. *Burden of tuberculosis related to HIV: new estimates and projections*. Provisional estimates and projections presented during the first meeting of the Global TB/HIV working group. April 9–11, 2001. Geneva: World Health Organization, 2001.
- 14 Republic of South Africa Department of Health. *National Antenatal HIV Sero-Prevalence Survey in South Africa, Health Systems Research and Epidemiology, Department of Health, Republic of South Africa, final report*. Johannesburg: Department of Health, 1999.
- 15 Raviglione MC, Harries AD, Msiska R, et al. Tuberculosis and HIV: current status in Africa. *AIDS*. 1997;11 Suppl B:S115-23.
- 16 UNAIDS, *Report on the Global HIV-AIDS Epidemic*, June 2000, Joint United Nations Program on HIV-AIDS, Geneva
- 17 UNAIDS, “UNAIDS Epidemic Update. December 2001” UNAIDS, Geneva 2001.
- 18 Corbett EL, Watt CJ, Walker N, Maher D, Raviglione MC, Williams B, Dye C. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic (submitted for publication)
- 19 UNAIDS, *Report on the Global HIV-AIDS Epidemic*, June 2000, Joint United Nations Program on HIV-AIDS, Geneva
- 20 Lucas SB, Hounnou A, Peacock C, et al. The mortality and pathology of HIV infection in a West African city. *AIDS* 1993; 7: 1569-1579
- 21 Sawert H, Kongsin S, Payanandana V, et al. Costs and benefits of improving tuberculosis control: the case of Thailand. *Soc Sci Med*. 1997;44:1805–16.
- 22 Bechu, N. The impact of AIDS on the economy of families in Cote d’Ivoire: Changes in consumption among AIDS-affected households. In: Ainsworth M, Over AM. *Confronting AIDS : Evidence From the Developing World Selected Background Papers for the World Bank Policy Research Report, Confronting AIDS: Public Priorities in a Global Epidemic*. Brussels and Washington: European Commission and World Bank, 1998.
- 23 Ahlburg DA. *The economic impacts of tuberculosis*. Geneva: World Health Organization, 2000. WHO/CDS/STB/2000.5.
- 24 Stover J, and Bollinger L. *Current Opinion in Infectious Diseases*. 1999;12(3):271–315.
- 25 http://www.usaid.gov/pop_health/aids/Countries/africa/kenya.html
- 26 http://www.unaids.org/whatsnew/adf/files/eco_impact.pdf
- 27 Hansen K, Chapman G, Chitsike I, et al. The costs of HIV/AIDS care at government hospitals in Zimbabwe. *Health Policy Plan*. 2000;15:432–40.
- 28 World Health Organization. *Global TB Control: WHO Report 2001*. Geneva: World Health Organization, 2001.
- 29 Chaisson RE, Clermont HC, Holt EA, et al. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. *Am J Respir Crit Care Med*. 1996;154:1034–8; el-Sadr WM, Perlman DC, Matts JP, et al. Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Bein Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG). *Clin Infect Dis*. 1998;26:1148–58;

- Perriens JH, St Louis ME, Mukadi YB, et al. Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months. *N Engl J Med.* 1995;332:779–84; Small PM, Schechter GE, Goodman PC, Sande MA, Chaisson RE, Hopewell PC. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. *N Engl J Med.* 1991;324:289–94.
- 30 Heymann SJ. Modelling the efficacy of prophylactic and curative therapies for preventing the spread of tuberculosis in Africa. *Trans R Soc Trop Med Hyg.* 1993;87:406–11.
- 31 Brazilian Ministry of Health, National STD/AIDS Programme. *Antiretroviral Therapy: Brazil's Experience.* Brasilia: Brazilian Ministry of Health, 2001.
- 32 http://www.unaids.org/hivaidsinfo/statistics/fact_sheets/pdfs/Argentina_en.pdf
- 33 Hirschel, Bernard, HIV/AIDS Unit, Hopital Cantonal, Geneva. *Reasons why treatment of TB must be combined with HAART.* Presented during the first meeting of the Global TB/HIV working group. April 9–11, 2001. Geneva: World Health Organization, 2001.
- 34 Nunn P, Brindle R, Carpenter L, et al. Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya. Analysis of early (6-month) mortality. *Am Rev Respir Dis.* 1992;146:849–54.
- 35 Farmer P, Leandre F, Mukherjee JS, et al. Community-based approaches to HIV treatment in resource-poor settings. *Lancet.* 2001;358:404–9.
- 36 Odhiambo JA, Borgdorff MW, Kiambih FM, et al. Tuberculosis and the HIV epidemic: increasing annual risk of tuberculous infection in Kenya, 1986–1996. *Am J Public Health.* 1999;89:1078–82.
- 37 Mukadi YD, Maher D, Harries A. Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. *AIDS.* 2001;15:143–52.
- 38 Yanai H, Uthairavit W, Panich V, et al. Rapid increase in HIV-related tuberculosis, Chiang Rai, Thailand, 1990–1994. *AIDS.* 1996;10:527–31.
- 39 Dye, C. (2000) Tuberculosis 2000–2010: control, but not elimination. *International Journal of Tuberculosis and Lung Disease* 4, suppl. 2, S146–S152
- 40 Farmer P, Leandre F, Mukherjee JS, et al. Community-based approaches to HIV treatment in resource-poor settings. *Lancet.* 2001;358:404–9.
- 41 United Nations Development Programme. *Human Development Report 2000.* New York: Oxford University Press (for UNDP), 2000.
- 42 World Bank. Poverty reduction and human development in the Caribbean: a cross-country study. World Bank Discussion Paper; WDP 366, 1997.
- 43 Deschamps MM, Pape JW, Williams-Russo P, Madhavan S, Ho J, Johnson W. A prospective study of HIV-seropositive asymptomatic women of childbearing age in a developing country. *J Acquir Immune Defic Syndr* 1993; 6: 446–51.
- 44 UNAIDS. *Report on the global HIV/AIDS epidemic, June 2000.* Geneva: UNAIDS, 2000.
- 45 Central Intelligence Agency. *The world factbook 2000.* Washington: CIA, 2000. Internet communication at: <http://www.odci.gov/cia/publications/factbook/geos/ha.html>.
- 46 Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. *N Engl J Med.* 1994;331:1173–80.
- 47 Centers for Disease Control and Prevention. Update: provisional Public Health Service recommendations for chemoprophylaxis after occupational exposure to HIV. *MMWR Morb Mortal Wkly Rep.* 1996;45:468–80.
- 48 Farmer P, Leandre F, Mukherjee JS, et al. Community-based approaches to HIV treatment in resource-poor settings. *Lancet.* 2001;358:404–9.
- 49 Perriens, Jos. Presented during the first meeting of the Global TB/HIV working group. April 9–11, 2001. Geneva: World Health Organization, 2001.
- 50 Maher D, Floyd K, Raviglione M. A strategic framework to decrease the burden of TB/HIV. WHO/CDS/TB/2002.296 World Health Organization, Geneva.

CHAPTER 4

- 1 Bureau of Tuberculosis Control. *Bureau of Tuberculosis Control Information Summary: 1998.* New York: New York City Department of Health, 1999.
- 2 Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York City—turning the tide. *N Engl J Med.* 1995;333:229–33.
- 3 Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons—Florida and New York, 1988–1991. *MMWR Morb Mortal Wkly Rep.* 1991;40:585–91.
- 4 Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York City—turning the tide. *N Engl J Med.* 1995;333:229–33.
- 5 Fujiwara PI, Larkin C, Frieden TR. Directly observed therapy in New York City. History, implementation, results, and challenges. *Clin Chest Med.* 1997;18:135–48.
- 6 Bureau of Tuberculosis Control. *Bureau of Tuberculosis Control Information Summary: 1998.* New York: New York City Department of Health, 1999.
- 7 Bureau of Tuberculosis Control. *Bureau of Tuberculosis Control Information Summary: 1998.* New York: New York City Department of Health, 1999.
- 8 Gasner MR, Maw KL, Feldman GE, et al. The use of legal action in New York City to ensure treatment of tuberculosis. *N Engl J Med.* 1999;340:359–66.
- 9 New York City Department of Health, unpublished data.
- 10 Tuberculosis among foreign-born persons entering the United States. Recommendations of the Advisory Committee for Elimination of Tuberculosis. *MMWR Morb Mortal Wkly Rep.* 1990;39:1–21.

- 11 Crofton J, Chaulet P, and Mahler D. *Guidelines for the management of drug resistant tuberculosis*. Geneva: World Health Organization, 1996. WHO/TB/96.21 (Rev/1).
- 12 Iseman MD. Tailoring a time-bomb. Inadvertent genetic engineering. *Am Rev Respir Dis*. 1985;132:735–6; Grzybowski S, Enarson D. [Results in pulmonary tuberculosis patients under various treatment program conditions]. *Bull Int Union Tuberc*. 1978;53:70–5; Fischer B. Epidemiology of mycobacterial resistance (especially *Mycobacterium tuberculosis*). *Chemotherapy* 1999;45:109–20.
- 13 Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. *N Engl J Med*. 1994;330:1179–84; World Health Organization. *Global Tuberculosis Control: WHO Report 1999*. Geneva: World Health Organization, 1999.
- 14 Beck-Sague C, Dooley SW, Hutton MD, et al. Hospital outbreak of multidrug-resistant *Mycobacterium tuberculosis* infections. Factors in transmission to staff and HIV-infected patients. *JAMA*. 1992;268:1280–6; Di Perri G, Cadeo GP, Castelli F, et al. Transmission of HIV-associated tuberculosis to health-care workers. *Lancet*. 1992;340:682; Pearson ML, Jereb JA, Frieden TR, et al. Nosocomial transmission of multidrug-resistant *Mycobacterium tuberculosis*. A risk to patients and health care workers. *Ann Intern Med*. 1992;117:191–6.
- 15 World Health Organization, International Union Against Tuberculosis and Lung Disease. *Anti-tuberculosis drug resistance in the world: The WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance 1994–1997*. Geneva: World Health Organization, 1997; WHO. *Global Tuberculosis control: WHO report 2000*. Geneva: World Health Organization, 2000; World Health Organization. *Anti-TB drug resistance in the world. Report n° 2*. Geneva: WHO/IUATLD Global Project on antituberculosis drug resistance surveillance, 2000. WHO/CDS/TB/2000.278.
- 16 Dye C, Espinal M, Watt C, Mbiaga C, Williams B, *Worldwide incidence of multidrug-resistant tuberculosis*, unpublished; Espinal MA, Laszlo A, Simonsen L, et al. Global trends in resistance to antituberculosis drugs. World Health Organization—International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. *N Engl J Med*. 2001;344:1294–303; Mercedes Becerra (personal communication); World Health Organization, International Union Against Tuberculosis and Lung Diseases, *Anti-tuberculosis Drug Resistance in the World, Report n°2 Prevalence and trends, WHO–IUATLD Global project on anti-tuberculosis drug resistance surveillance*. Geneva: World Health Organization, 2000. WHO/CDS/TB/2000; Program in Infectious Disease and Social Change. *The global impact of drug-resistant tuberculosis*. Boston: Harvard University and Open Society Institute, 1999.
- 17 Program in Infectious Disease and Social Change. *The global impact of drug-resistant tuberculosis*. Boston: Harvard University and Open Society Institute, 1999.
- 18 Bifani PJ, Plikaytis BB, Kapur V, et al. Origin and interstate spread of a New York City multidrug-resistant *Mycobacterium tuberculosis* clone family. *JAMA*. 1996;275:452–7; Agerton TB, Valway SE, Blinkhorn RJ, et al. Spread of strain W, a highly drug-resistant strain of *Mycobacterium tuberculosis*, across the United States. *Clin Infect Dis*. 1999;29:85–92; discussion 93–5.
- 19 Casper C, Singh SP, Rave S, et al. The transcontinental transmission of tuberculosis: A molecular epidemiological assessment. *Am J Public Health*. 1996;86:551–3; Codina G, Vidal R, Martin-Casabona N, et al. Multidrug-resistant tuberculosis caused by "W"-related strains in three immunocompetent foreign-born patients. *Int J Tuberc Lung Dis*. 1999;3:82–4.
- 20 Borchartd J, Kirsten D, Jorres R, et al. Drug-resistant tuberculosis in northern Germany: a retrospective hospital-based study of 1,055 patients from 1984 until 1993. *Eur Respir J*. 1995;8:1076–83; Lambregts van Weezenbeek CS, Jansen HM, Nagelkerke NJ, et al. Nationwide surveillance of drug-resistant tuberculosis in The Netherlands: rates, risk factors and treatment outcome. *Int J Tuberc Lung Dis*. 1998;2:288–95; Codecaca LR, Porretta AD, Gori A, et al. Tuberculosis among immigrants from developing countries in the province of Milan, 1993–1996. *Int J Tuberc Lung Dis*. 1999;3:589–95.
- 21 CDC. (1999). Primary multidrug-resistant tuberculosis—Ivanovo Oblast, Russia, 1999. *Morbidity & Mortality Weekly Report*, 48(30):661–3.; Coninx, R., Mathieu, C., Debacker, M., Mirzoev, F., Ismaelov, A., de Haller, R., and Meddings, D.R. (1999). First-line tuberculosis therapy and drug-resistant *Mycobacterium tuberculosis* in prisons. *Lancet*, 353, 969–973.; Kimerling, M.E., Kluge, H., Vezhnina, N., Iacovazzi, T., Demeulenaere, T., Portaels, F., and Matthys, F. (1999). Inadequacy of the current WHO re-treatment regimen in a central Siberian prison: treatment failure and MDR-TB. *International Journal of Tuberculosis Lung Disease*, 3(5), 451–453.
- 22 Manalo F, Tan F, Sbarbaro JA, Iseman MD. Community-based short-course treatment of pulmonary tuberculosis in a developing nation. Initial report of an eight-month, largely intermittent regimen in a population with a high prevalence of drug resistance. *Am Rev Respir Dis*. 1990;142:1301–5; Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. *Am Rev Respir Dis*. 1986;133:423–30; Shimao T. Drug resistance in tuberculosis control. *Tubercle*. 1987;68:5–18; Espinal MA, Kim SJ, Suárez PG, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. *JAMA*. 2000;283:2537–45; Hauer B, Serke M, Loddenkemper R, et al. Various polyresistant strains of *M. tuberculosis* in one patient (case report). *Int J Tuberc Lung Dis*. 1999;3(9 Suppl. 1):S122.
- 23 Espinal MA, Kim SJ, Suárez PG, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. *JAMA*. 2000;283:2537
- 24 Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York City—turning the tide. *N Engl J Med*. 1995;333:229–33; Arno PS, Murray CJ, Bonuck KA, Alcibes P. The economic impact of tuberculosis in hospitals in New York City: a preliminary analysis. *J Law Med Ethics*. 1993;21:317–23.
- 25 Appaix, Olivier. *Tuberculosis Control: Financial Evaluation for the 2001–2005 Period (in Low- and Lower Middle-Income Countries)*. *Economic Annex to the Global Plan to Stop TB* Boston: Partners In Health, to be published in 2002.
- 26 Geerligs WA, van Altena R, van der Werf TS. Antituberculosis-drug resistance. *N Engl J Med*. 1998;339:1079–80.
- 27 World Health Organization. *Guidelines for the Management of Drug-Resistant Tuberculosis*. Geneva: World Health Organization, 1996. WHO/TB/96.210.
- 28 Furin JJ, Mitnick CD, Shin SS, et al. Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. *Int J Tuberc Lung Dis*. 2001;5:648–55.
- 29 Kritski AL, Marques MJ, Rabahi MF, et al. Transmission of tuberculosis to close contacts of patients with multidrug-resistant tuberculosis. *Am J Respir Crit Care Med*. 1996;153:331–5; Raviglione MC, Snider DE Jr, Kochi A. Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. *JAMA*. 1995;273:220–6; Snider DE Jr, Kelly GD, Cauthen GM, et al. Infection and disease among contacts of tuberculosis cases with drug-resistant and drug-susceptible bacilli. *Am Rev Respir Dis*. 1985;132:125–32; Teixeira L, Perkins MD, Johnson JL, et al. Infection

- and disease among household contacts of patients with multidrug-resistant tuberculosis. *Int J Tuberc Lung Dis.* 2001;5:321–8; Agerton T, Valway S, Gore B, et al. Transmission of a highly drug-resistant strain (strain W1) of *Mycobacterium tuberculosis*. Community outbreak and nosocomial transmission via a contaminated bronchoscope. *JAMA.* 1997;278:1073–7; Victor TC, Warren R, Beyers N, van Helden PD. Transmission of multidrug-resistant strains of *Mycobacterium tuberculosis* in a high incidence community. *Eur J Clin Microbiol Infect Dis.* 1997;16:548–9; Warren R, Hauman J, Beyers N, et al. Unexpectedly high strain diversity of *Mycobacterium tuberculosis* in a high-incidence community. *S Afr Med J.* 1996;86:45–9.
- ³⁰Beck-Sague C, Dooley SW, Hutton MD, et al. Hospital outbreak of multidrug-resistant *Mycobacterium tuberculosis* infections. Factors in transmission to staff and HIV-infected patients. *JAMA.* 1992;268:1280–6; Di Perri G, Cadeo GP, Castelli F, et al. Transmission of HIV-associated tuberculosis to healthcare workers. *Infect Control Hosp Epidemiol.* 1993;14:67–72; Valway SE, Greifinger RB, Papania M, et al. Multidrug-resistant tuberculosis in the New York State prison system, 1990–1991. *J Infect Dis.* 1994;170:151–6; Transmission of multidrug-resistant tuberculosis among immunocompromised persons in a correctional system—New York, 1991. *MMWR Morb Mortal Wkly Rep.* 1992;41:507–9.
- ³¹World Health Organization. *Anti-tuberculosis drug resistance in the world: the WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance 1994–1997.* Geneva: World Health Organization, 1997; World Health Organization, International Union Against Tuberculosis and Lung Diseases. *Anti-tuberculosis Drug Resistance in the World, Report n°2 Prevalence and trends.* WHO-IUATLD Global project on anti-tuberculosis drug resistance surveillance. Geneva: World Health Organization, 2000. WHO/CDS/TB/2000.
- ³²Garrett L; *The Coming Plague: Newly Emerging Diseases in a World Out of Balance.* New York: Farrar, Straus and Giroux, 1994.
- ³³Bifani PJ, Plikaytis BB, Kapur V, et al. Origin and interstate spread of a New York City multidrug-resistant *Mycobacterium tuberculosis* clone family. *JAMA.* 1996;275:452–7.
- ³⁴Franzetti F, Gori A, Iemoli E, et al. Outcome of multidrug-resistant tuberculosis in human immunodeficiency virus-infected patients. *Clin Infect Dis.* 1999;29:553–60; Moro ML, Gori A, Errante I, et al. An outbreak of multidrug-resistant tuberculosis involving HIV-infected patients of two hospitals in Milan, Italy. Italian Multidrug-Resistant Tuberculosis Outbreak Study Group. *AIDS.* 1998;12:1095–102; Moro ML, Errante I, Infuso A, et al. Effectiveness of infection control measures in controlling a nosocomial outbreak of multidrug-resistant tuberculosis among HIV patients in Italy. *Int J Tuberc Lung Dis.* 2000;4:61–8.
- ³⁵Weyer K, Groenewald P, Zwarenstein M, Lombard CJ. Tuberculosis drug resistance in the Western Cape. *S Afr Med J.* 1995;85:499–504; Weyer K, Lancaster J, Balt E, Durrheim D. Tuberculosis drug resistance in Mpumalanga Province, South Africa. *Int J Tuberc Lung Dis.* 1998;2(11 Suppl. 2):S332–3.
- ³⁶World Health Organization. *Global Tuberculosis Control. WHO Report 2000.* Geneva: World Health Organization, 2000. WHO/CDS/TB/2000.275.
- ³⁷Cantwell MF, Binkin NJ. Tuberculosis in sub-Saharan Africa: a regional assessment of the impact of the human immunodeficiency virus and National Tuberculosis Control Program quality. *Tuber Lung Dis.* 1996;77:220–5; Cantwell MF, Binkin NJ. Impact of HIV on tuberculosis in sub-Saharan Africa: a regional perspective. *Int J Tuberc Lung Dis.* 1997;1:205–14; Richards SB, St Louis ME, Nieburg P, et al. Impact of the HIV epidemic on trends in tuberculosis in Abidjan, Cote d'Ivoire. *Tuber Lung Dis.* 1995;76:11–6; World Health Organization. *Global Tuberculosis Control. WHO Report 2000.* Geneva: World Health Organization, 2000. WHO/CDS/TB/2000.275; World Health Organization. *Tuberculosis and Sustainable Development: Report from the Ministerial Conference in Amsterdam.* Geneva: World Health Organization, 2000. WHO/CDS/STB/2000.6.
- ³⁸Sacks LV, Pendle S, Orlovic D, et al. A comparison of outbreak- and nonoutbreak-related multidrug-resistant tuberculosis among human immunodeficiency virus-infected patients in a South African hospital. *Clin Infect Dis.* 1999;29:96–101; Silber E, Sonnenberg P, Saffer D, Koornhof HJ. Multidrug-resistant tuberculous meningitis in a health care worker. *Int J Tuberc Lung Dis.* 1998;2:774; van Rie A, Warren R, Richardson M, et al. Transmission of drug-resistant *Mycobacterium tuberculosis* strains in an epidemic area. *Int J Tuberc Lung Dis.* 1999;3(9 Suppl. 1):S126.
- ³⁹Becerra MC, Freeman J, Bayona J, et al. Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis. *Int J Tuberc Lung Dis.* 2000;4:108–14; Becerra MC, Freeman J, Bayona J, et al. Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis. *Int J Tuberc Lung Dis.* 2000;4:108–14.
- ⁴⁰Primary multidrug-resistant tuberculosis—Ivanovo Oblast, Russia, 1999. *MMWR Morb Mortal Wkly Rep.* 1999;48:661–4; Cegielski JP, Repina E, Laserson K, et al. Preparation for DOTS-Plus pilot project in Ivanovo, Russia. *Int J Tuberc Lung Dis.* 1999;3(9 Suppl. 1):S86; Kimerling ME, Kluge H, Vezhnina N, et al. Inadequacy of the current WHO re-treatment regimen in a central Siberian prison: treatment failure and MDR-TB. *Int J Tuberc Lung Dis.* 1999;3:451–3; Farmer, P.E., Kim, J.Y., Mitnick, C., Timperi, R. Responding to outbreaks of MDR-TB: Introducing “DOTS-Plus”. In: Reichman LB, Hershfield ES. *Tuberculosis a Comprehensive International Approach.* New York: Marcel Dekker, 2000.
- ⁴¹World Health Organization. *Global Tuberculosis Control: WHO Report 2000.* Geneva: World Health Organization, 2000. WHO/CDS/TB/2000.275.
- ⁴²Kim SJ, Bai GH, Hong YP. Drug-resistant tuberculosis in Korea, 1994. *Int J Tuberc Lung Dis.* 1997;1:302–8.
- ⁴³Kim SJ, Hong YP. Drug resistance of *Mycobacterium tuberculosis* in Korea. *Tuber Lung Dis.* 1992;73:219–24.
- ⁴⁴Park SK, Kim CT, Song SD. Outcome of chemotherapy in 107 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. *Int J Tuberc Lung Dis.* 1998;2:877–84; World Health Organization, International Union Against Tuberculosis and Lung Diseases. *Anti-tuberculosis Drug Resistance in the World, Report n°2 Prevalence and trends.* WHO-IUATLD Global project on anti-tuberculosis drug resistance surveillance. Geneva: World Health Organization, 2000. WHO/CDS/TB/2000.
- ⁴⁵World Health Organization, International Union Against Tuberculosis and Lung Diseases. *Anti-tuberculosis Drug Resistance in the World, Report Number 2 Prevalence and trends.* WHO-IUATLD Global project on anti-tuberculosis drug resistance surveillance. Geneva: World Health Organization, 2000. WHO/CDS/TB/2000; World Health Organization. *Global Tuberculosis Control. WHO Report 2000.* Geneva: World Health Organization, 2000. WHO/CDS/TB/2000.275.
- ⁴⁶Kim JY, Bayona J, Furin JJ, et al. Making DOTS-Plus work: Laboratories, drug procurement, planning, and evaluation. In: Programme in Infectious Disease and Social Change. *The global impact of drug-resistant Tuberculosis.* Boston: Harvard University and Open Society Institute, 1999.

- ⁴⁷ Banatvala N, Matic S, Kimerling M, et al. Tuberculosis in Russia. *Lancet*. 1999;354:1036.
- ⁴⁸ Farmer P, Kim JY. Community based approaches to the control of multidrug resistant tuberculosis: introducing "DOTS-plus". *BMJ*. 1998;317:671-4; Farmer PE, Kim JY, Mitnick C, Timperi R. Responding to outbreaks of MDR-TB: Introducing "DOTS-Plus". In: Reichman LB, Hershfield ES; *Tuberculosis a Comprehensive International Approach*. New York: Marcel Dekker, 2000; Becerra MC, Freeman J, Bayona J, et al. Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis. *Int J Tuberc Lung Dis*. 2000;4:108-14.
- ⁴⁹ Farmer PE, Bayona J, Shin S, et al. Preliminary results of community-based MDR-TB treatment in Lima, Peru. *Int J Tuberc Lung Dis*. 1998;2(11 Suppl. 2):S371; Farmer P, Kim JY. Community based approaches to the control of multidrug resistant tuberculosis: introducing "DOTS-plus". *BMJ*. 1998;317:671-4; Farmer PE, Bayona J, Becerra M, et al. Poverty, inequality, and drug resistance: Meeting community needs. *Proceedings of the International Union Against Tuberculosis and Lung Disease North American Region Conference*. Chicago, February 27-March. 2, 1997. Chicago: International Union Against Tuberculosis and Lung Disease, 1997, pp. 88-102; Farmer PE, Bayona J, Becerra MC, et al. International Working Group on Multidrug-Resistant Tuberculosis. The emergence of MDR-TB in urban Peru: A population-based study using conventional, molecular, and ethnographic methods. *Int J Tuberc Lung Dis*. 1997;1(5, S1):S44.
- ⁵⁰ Farmer P, Kim JY. Community based approaches to the control of multidrug-resistant tuberculosis: introducing "DOTS-plus". *BMJ*. 1998;317:671-4; Farmer PE, Kim JY, Mitnick C, Timperi R. Responding to outbreaks of MDR-TB: Introducing "DOTS-Plus". In: Reichman LB, Hershfield ES; *Tuberculosis a Comprehensive International Approach*. New York: Marcel Dekker, 2000; Grosset PJ. Systematic drug susceptibility testing: a necessary component of the "DOTS plus" strategy? *Int J Tuberc Lung Dis*. 1999;3:549-50; Iseman MD. MDR-TB and the developing world--a problem no longer to be ignored: the WHO announces "DOTS Plus" strategy. *Int J Tuberc Lung Dis*. 1998;2:867; Portaels F, Rigouts L, Bastian I. Addressing multidrug-resistant tuberculosis in penitentiary hospitals and in the general population of the former Soviet Union. *Int J Tuberc Lung Dis*. 1999;3:582-8; World Health Organization. *Coordination of DOTS-Plus pilot projects for the management of MDR-TB*. Geneva: World Health Organization, 1999. WHO/CDS/CBC/TB/99.262.
- ⁵¹ Farmer P, Kim JY. Community based approaches to the control of multidrug resistant tuberculosis: introducing "DOTS-plus". *BMJ*. 1998;317:671-4; Farmer PE, Kim JY, Mitnick C, Timperi R. Responding to outbreaks of MDR-TB: Introducing "DOTS-Plus". In: Reichman LB, Hershfield ES; *Tuberculosis a Comprehensive International Approach*. New York: Marcel Dekker, 2000; World Health Organization. *Coordination of DOTS-Plus pilot projects for the management of MDR-TB*. Geneva: World Health Organization, 1999. WHO/CDS/CBC/TB/99.262.
- ⁵² World Health Organization. *Coordination of DOTS-Plus pilot projects for the management of MDR-TB*. Geneva: World Health Organization, 1999. WHO/CDS/CBC/TB/99.262.
- ⁵³ Program in Infectious Disease and Social Change. *The global impact of drug-resistant tuberculosis*. Boston: Harvard University and Open Society Institute, 1999; Farmer P, Kim JY. Community based approaches to the control of multidrug-resistant tuberculosis: introducing "DOTS-plus". *BMJ*. 1998;317:671-4.
- ⁵⁴ Iseman MD. Treatment of multidrug-resistant tuberculosis. *N Engl J Med*. 1993;329:784-91; Furin JJ, Mitnick CD, Shin SS, et al. Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. *Int J Tuberc Lung Dis*. 2001;5:648-55.
- ⁵⁵ World Health Organization. *Anti-tuberculosis drug resistance in the world: the WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance 199-1997*. Geneva: World Health Organization, 1997; Laszlo A, Rahman M, Raviglione M, Bustreo F. Quality assurance programme for drug susceptibility testing of *Mycobacterium tuberculosis* in the WHO/IUATLD Supranational Laboratory Network: first round of proficiency testing. *Int J Tuberc Lung Dis*. 1997;1:231-8.

CHAPTER 5

- ¹ Ryan F. *The Forgotten Plague: How the Battle Against Tuberculosis Was Won--and Lost*. Boston: Little, Brown, 1993.
- ² Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. *Int J Tuberc Lung Dis*. 1999;3 (10 Suppl 2):S231-79.
- ³ Michaud C and Murray CJL. Annex 5. Resources for health research and development in 1992: A global overview. In: *Investing in Health Research and Development: Report of the Ad Hoc Committee on Health Research Relating to future intervention options*. Geneva: World Health Organization, 1996.
- ⁴ Nunn P and Linkins J. *The Global Tuberculosis Research Initiative: Research to make a difference*. Geneva: World Health Organization, 1998. WHO/TB/98.248.
- ⁵ Cole ST, Brosch R, Parkhill J, et al. Deciphering the biology of *Mycobacterium tuberculosis* from the complete genome sequence. *Nature*. 1998;393:537-44.
- ⁶ Foulds J and O'Brien R. New tools for the diagnosis of tuberculosis: the perspective of developing countries. *Int J Tuberc Lung Dis*. 2000;10:778-83; Perkins MD. New diagnostic tools for tuberculosis. *Int J Tuberc Lung Dis*. 2000;12 (Supplement):S182-8.
- ⁷ Chang-Blanc D, and Nunn P. *Incentives and disincentives for new anti-tuberculosis drug development: situational analysis*. Geneva: World Health Organization, 2000. WHO/TDR/PRD/TB/00.1.
- ⁸ Global Alliance for TB Drug Development, *The Economics of TB Drug Development*. New York: Global Alliance for TB Drug Development, 2001.
- ⁹ Boston Consulting Group, for the Global Alliance for TB Drug Development, 2000 (personal communication).
- ¹⁰ Sachs J. Helping the world's poorest. *The Economist*. August 12, 1999; Sachs J. A new map of the world. *The Economist*. June 24, 2000.
- ¹¹ Salaniponi F, Harries AD, Nyirenda T, et al. *Putting research into policy and practice: The experience of the Malawi National Tuberculosis Programme*. Geneva: World Health Organization, 1999. WHO/CDS/CPC/TB/99.268.
- ¹² Crofton J. Sputum conversion and the metabolism of isoniazid. *American Review of Tuberculosis*. 1958;77:869-871.
- ¹³ Styblo K, Chum HJ. Treatment results of smear-positive tuberculosis in the Tanzania National Tuberculosis and Leprosy Programme: standard and short-course chemotherapy. In: *Proceedings of the XXVI IUAT World Conference on Tuberculosis and Respiratory Diseases*. Tokyo: Professional

Postgraduate Services, 1987:122–6.

¹⁴The International Network for the Rational Use of Drugs (INRUD), 2000. Internet communication at: <http://www.msh.org/inrud/> ; Hogerzeil HV, Bimo, Ross-Degnan D, et al. Field tests for rational drug use in twelve developing countries. *Lancet*. 1993;342:1408–10.

¹⁵WHO. *Report of the Ad Hoc Committee on the tuberculosis epidemic, London*. Geneva: World Health Organization, 1998. TB/98.245.

¹⁶WHO. *Report of the First Meeting of the Global TB Research Initiative*. Geneva: World Health Organization, 1998. TB/98.245.